




Scout Out Canine Hemangiosarcoma (SOCH) Study

UW Veterinary Cancer Center is enrolling dogs with hemangiosarcoma (HSA) in a vaccine immunotherapy clinical trial

UW Veterinary Cancer Center



Scout was taken too soon from HSA

- HSA is a common, uniformly fatal cancer that starts in the spleen of dogs
- This trial seeks to stimulate the patients own immune system to "Scout Out" and kill the cancer cells
- After spleen removal, **ALL** dogs will receive the current Standard-of-Care treatment involving chemotherapy **plus**:
 - half of the dogs will receive an investigational anti-cancer vaccine designed against 36 potential immune targets specific to HSA cancer in addition to the standard chemotherapy
 - half of the dogs will receive a non-therapeutic control vaccine (placebo) in addition to the standard chemotherapy
- Patients will receive treatment and follow-up rechecks over the course of a year.

Eligibility:

- Dogs must weigh ≥ 5 kg (11 lbs).
- Dogs must have a biopsy confirmed diagnosis of splenic hemangiosarcoma, stage I or II.
- Dogs must have undergone a splenectomy within the 3 weeks preceding trial entry.
- Other eligibility requirements are established at the first visit.

This fully funded study pays for:

- All required examination visits
- Lab work (CBC, blood chemistry, urinalysis)
- Diagnostics every 8 weeks (thoracic radiographs and abdominal ultrasound)
- Standard of care chemotherapy (Doxorubicin) x 5 cycles
- The study does **not** pay for splenectomy which is required for diagnosis

For more information and to request entry into this clinical trial please contact us at: **Email:** oncclinicaltrials@vetmed.wisc.edu **Phone:** (608)-890-0422